Literature DB >> 14350199

Observations on the pathogenicity of isoniazid-resistant mutants of tubercle bacilli for tuberculous patients.

R OESTREICHER, S H DRESSLER, W F RUSSELL, J B GROW, G MIDDLEBROOK.   

Abstract

Entities:  

Keywords:  MYCOBACTERIUM TUBERCULOSIS/effect of drugs on; TUBERCULOSIS/pathology

Mesh：

Substances：

Year:  1955        PMID： 14350199     DOI： 10.1164/artpd.1955.71.3-1.390

Source DB:  PubMed          Journal:  Am Rev Tuberc        ISSN： 0096-0381


× No keyword cloud information.
  5 in total

1.  Advanced pulmonary tuberculosis with persistent cavitation; preliminary report on prolonged chemotherapy.

Authors:  A C DOUGLAS; N W HORNE
Journal:  Br Med J       Date:  1956-02-18

2.  The course of pulmonary tuberculosis in patients excreting organisms which have acquired resistance. Response to continued treatment for a second year with isoniazid alone or with isoniazid plus PAS.

Authors:  C V RAMAKRISHNAN; A L BHATIA; S DEVADATTA; W FOX; A S NARAYANA; J B SELKON; S VELU
Journal:  Bull World Health Organ       Date:  1962       Impact factor: 9.408

3.  Prospective study of drug-resistant tuberculosis in a Spanish urban population including patients at risk for HIV infection.

Authors:  V Ausina; N Riutort; B Viñado; J M Manterola; J Ruiz Manzano; C Rodrigo; L Matas; M Giménez; J Tor; J Roca
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-02       Impact factor: 3.267

4.  Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis. 2. Clinical implications in the treatment of pulmonary tuberculosis with isoniazid either alone or in combination with PAS.

Authors:  J B SELKON; W FOX; P R GANGADHARAM; K RAMACHANDRAN; C V RAMAKRISHNAN; S VELU
Journal:  Bull World Health Organ       Date:  1961       Impact factor: 9.408

5.  A concurrent comparison of isoniazid plus PAS with three regimens of isoniazid alone in the domiciliary treatment of pulmonary tuberculosis in South India.

Authors: 
Journal:  Bull World Health Organ       Date:  1960       Impact factor: 9.408
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.